PremiumRatingsPromising Growth and Strategic Moves Justify Buy Rating for Iovance Biotherapeutics Closing Bell Movers: HP slips 4% as guidance disappoints; Elastic up 15% Iovance Biotherapeutics reports Q4 EPS (26c), consensus (27c) PremiumThe FlyIovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler Iovance Biotherapeutics promotes Raj Puri to chief regulatory officer Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency PremiumThe FlyIovance Biotherapeutics reports Q3 EPS (28c), consensus (30c) Unusually active option classes on open November 5th IOVA Earnings Report this Week: Is It a Buy, Ahead of Earnings? 
